Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models

Clinical Cancer Research

Volumn 6, Issue 10, 2000, Pages 4110-4118

  Houghton, P J ^a   Stewart, C F ^a   Cheshire, P J ^a   Richmond, L B ^a   Kirstein, M N ^a   Poquette, C A ^a   Tan, M ^a   Friedman, H S ^a   Brent, T P ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG POTENTIATION; FEMALE; GLIOBLASTOMA; MOUSE; NEUROBLASTOMA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; XENOGRAFT;

ADMINISTRATION, ORAL; ALKYLATING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE PAIR MISMATCH; BRAIN NEOPLASMS; CAMPTOTHECIN; DACARBAZINE; DNA REPAIR; FEMALE; GLIOBLASTOMA; MICE; MICE, INBRED CBA; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PHENOTYPE; RHABDOMYOSARCOMA; TIME FACTORS;

EID: 0033761232     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Cancer research campaign Phase II trial of temozolomide in metastatic melanoma
2. Multicentre CRC Pahse II trial of temozolomide in recurrent or progressive high-grade glioma
3. 6 alkylation in the mechanism of cytotoxicity of imidazotetrazines
4. 6-benzylguanine: A comparative study in vitro
5. 6-alkylguanine-DNA alkyltransferase attenuates triazene-induced cytotoxicity and tumor cell immunogenicity in murine L1210 leukemia
6. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenografts
7. Animal models for studying the action of topoisomerase-I targeted drugs
8. Irinotecan in cancers of the lung and cervix
9. Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies
10. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo
11. Potentiation of murine Mca-4 carcinoma radioresponse by 9-amino-20S-camptothecin
12. Advantages in combination chemotherapy using the camptothecin analogue CPT-11 and cisplatinum analogues for human testicular cancer xenografts
13. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents
14. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts
15. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects
16. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I
17. 6-Alkylation of guanine induces topoisomerase I-DNA covalent complexes in vitro and in MNNG-treated cells
18. Analysis of camptothecin resistance in yeast: Relevance to cancer therapy
19. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
20. Direct translation of a protracted irinotecan schedule from xenograft model to Phase I trial in children
21. Schedule dependent activity of temozolomide plus CPT-11 against a human central nervous system-derived xenograft
22. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice beating xenografts of human tumors
23. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylandnomethyl-10-hydroxycamptothecin
24. Efficacy of systemic administration of irinotecan against neuroblastoma xenografts
25. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts
26. Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft models
27. 14C-temozolomide following oral administration to patients with advanced cancer
28. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan
29. In vivo combination chemotherapy evaluations of topotecan with cisplatin and temozolomide
30. Temozolomide: A review of its discovery, chemical properties, pre-clinical development and clinical trials
31. Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice